Startup Nutrinia has lined up an impressive roster of investors to back what has been a long elusive achievement—the development of oral insulin.

Tioma Therapeutics plans to use part of the massive infusion of cash from its Series A round to jump into the Bay Area from St. Louis, MO.

There may be a slightly wider crack in the biotech IPO window this summer as Protagonist Therapeutics announces a larger-than-expected offering.

Motif Bio has had its Nasdaq IPO hopes crushed by an unreceptive market, leaving the late-phase antibiotic player with a hole in its spending plans.

The value of Neil Woodford’s Patient Capital Trust fell 10.8% as Circassia’s late-phase flop and the ongoing decline of Northwest Biotherapeutics hit home.

Ambrx has been around since it was founded in 2003. Now, the San Diego, CA-based startup has raised a latest financing of $45 million to support Phase I…

Life science VC firms have stumped up $25 million in a Series A raise for Cambridge, MA-based biotech Avrobio as it looks to take its gene therapy work into…

Bioniz Therapeutics is slated to start a Phase I trial for one of its cytokine inhibitors in partnership with the National Institutes of Health (NIH). Now, it’…